Jesus Guzman
Gastroenterology · El Paso, TXNPI 1326601956
Payments from drug & device makers
Across 120 payments — averaging $27.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$846
- Madrigal Pharmaceuticals$550
- Johnson & Johnson$510
- Takeda Pharmaceuticals U.S.A., Inc.$366
- Ardelyx, Inc.$295
- Cook Medical LLC$176
- plus $595 from 12 others
What the payments were for
- Food & beverage$3,15995%
- Education$1795%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $846 |
| Madrigal Pharmaceuticals | 6 | $550 |
| Johnson & Johnson | 23 | $510 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $366 |
| Ardelyx, Inc. | 9 | $295 |
| Cook Medical LLC | 4 | $176 |
| Phathom Pharmaceuticals, Inc. | 3 | $149 |
| Gilead | 5 | $109 |
| Pfizer | 6 | $106 |
| Sanofi | 1 | $41 |
| Ipsen Biopharmaceuticals, Inc | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 1 | $35 |
| Celltrion USA Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $23 |
| Novo Nordisk | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Boston Scientific | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$278
- Hemospray$148
- VOQUEZNA$125
- RESMETIROM$114
How this compares
$3,338 in reported general payments places this provider in the 45th percentile of 1,350 gastroenterology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 13 | $46,846 |
| LinzessLinaclotide | 15 | $13,347 |
| Mesalamine | 14 | $6,454 |
| Pantoprazole Sodium | 67 | $633 |
| Lactulose | 15 | $302 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 16 | $259 |
| Dicyclomine Hcl | 13 | $242 |
| Omeprazole | 15 | $209 |
| Propranolol Hcl | 14 | $190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $846 | $13,34715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in El Paso
- Emmanuel GorospeEl Paso$2.3M
- Eric LawitzSan Antonio$59.5M
- George DuvallTyler$17.5M
- John FordtranDallas$9.9M
- Timothy RitterSouthlake$7.7M
- Parvez MantryDallas$6.4M
- Mazen NoureddinHouston$6.1M
- Nadege GunnWaco$5.7M
- Michael BrownDallas$5.5M
- James MaherHouston$5.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.